Innovative Se-Flutamide Derivatives: Enhanced Activity Toward Androgen Receptor (AR)-Dependent and -Independent...

Area of Science:

• Medicinal Chemistry
• Oncology
• Molecular Biology

Background:

• Flutamide is a key treatment for androgen receptor (AR)-dependent prostate cancer.
• Developing novel therapeutics for AR-independent prostate cancer remains a critical challenge.
• Exploring selenoderivatives offers a promising avenue for enhanced anti-cancer efficacy.

Purpose of the Study:

• To synthesize and evaluate novel selenoderivatives of flutamide.
• To assess the antiproliferative activity of these compounds against a panel of human cancer cell lines, including AR-dependent and AR-independent prostate cancer models.
• To elucidate the mechanism of action for promising candidates.

Main Methods:

• Synthesis of sixteen novel selenoderivatives of flutamide.
• In vitro screening against the NCI-60 human cancer cell line panel.
• Assessment of antiproliferative effects on LNCaP, DU-145, and PC-3 prostate cancer cell lines.
• Apoptosis and cell cycle analysis using cell death inhibitors and flow cytometry.

Main Results:

• All synthesized selenoderivatives demonstrated promising activity against the NCI-60 panel.
• Compounds a2, a5, and b4 showed potent antiproliferative effects against AR-dependent LNCaP cells, unlike flutamide.
• Compound a5 induced apoptosis via intrinsic and extrinsic pathways, arrested cells in G0/G1 phase, and did not generate reactive oxygen species (ROS).

Conclusions:

• The novel Se-flutamide analogs exhibit significant potential for treating both AR-dependent and AR-independent prostate cancers.
• Compound a5 represents a promising candidate for further preclinical and clinical development.
• This research opens new therapeutic strategies for advanced prostate cancer treatment.